What Empliciti 400 mg is and what it is used for?
Empliciti 400 mg (elotuzumab), together with lenalidomide and dexamethasone, is a medicine used to treat multiple myeloma in patients who have received one to three previous treatments.
Empliciti 400 mg contains the active ingredient elotuzumab, which is a monoclonal antibody, a type of protein designed to recognize and bind to a specific target in the body. Elotuzumab binds to the target protein called SLAMF7. SLAMF7 is found in large amounts on the surface of multiple myeloma cells and on certain cells of our immune system (natural killer cells). When elotuzumab binds to SLAMF7 on multiple myeloma cells or natural killer cells, it stimulates your immune system to attack and destroy the multiple myeloma cells.
Empliciti is used to treat multiple myeloma (a cancer of the bone marrow) in adults. You will be given Empliciti together with lenalidomide and dexamethasone or together with pomalidomide and dexamethasone. Multiple myeloma is a cancer of a type of white blood cells called plasma cells. These cells divide uncontrollably and accumulate in the bone marrow. This causes damage to the bones and kidneys.
Empliciti is used if your cancer has not responded or has recurred after several treatments.
What you need to know before starting to use Empliciti
Composition of Empliciti
The active ingredient is elotuzumab.
Each vial of powder contains 300 mg or 400 mg of elotuzumab.
After reconstitution, each ml of concentrate contains 25 mg of elotuzumab.
The other ingredients (excipients) are sucrose, sodium citrate (see section 2 “Empliciti contains sodium”), citric acid monohydrate, and polysorbate 80 (E433).
Appearance of the product and contents of the container
Empliciti 400 mg powder for concentrate for solution for infusion (powder for concentrate) is presented in a white to off-white compact or fragmented form in a glass vial.
Empliciti is available in packs containing 1 vial.
